How to administer a Cardizem (diltiazem) push?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Administer a Cardizem (Diltiazem) Push

For rapid control of ventricular rate in atrial fibrillation/flutter or conversion of PSVT, administer intravenous diltiazem at a dose of 0.25 mg/kg (approximately 15-20 mg for an average adult) over 2 minutes, followed by continuous monitoring. 1, 2

Preparation and Administration

  • Ensure IV access is patent and functioning properly 2
  • Calculate the dose based on patient weight (0.25 mg/kg) 1
  • Draw up the calculated dose of diltiazem from the vial 2
  • Administer the dose slowly over 2 minutes via IV push 3, 1
  • Have resuscitation equipment readily available during administration 1, 2

Monitoring During Administration

  • Continuous ECG monitoring is essential throughout administration 2
  • Frequent blood pressure measurements should be taken before, during, and after administration 2
  • Monitor for hypotension, which is the most common adverse effect 4, 1
  • Watch for bradycardia and potential worsening of heart failure in predisposed patients 1

Dosing Considerations

  • Standard initial dose: 0.25 mg/kg IV over 2 minutes (approximately 15-20 mg for average adult) 1, 2
  • Some evidence suggests lower doses (≤0.2 mg/kg) may be equally effective with reduced risk of hypotension 5
  • For patients with atrial fibrillation/flutter, response usually occurs within 3 minutes with maximal heart rate reduction in 2-7 minutes 2
  • For PSVT, conversion to normal sinus rhythm typically occurs within 3 minutes of the first or second bolus dose 2

Follow-up Dosing

  • If inadequate response to initial dose, a second dose of 0.35 mg/kg may be given after 15 minutes 1
  • After successful rate control with IV bolus, consider continuous infusion at 5-15 mg/hour if needed 6
  • For transition to oral therapy, initiate oral diltiazem 4 hours before discontinuing IV infusion 6

Contraindications and Cautions

  • Avoid in patients with pre-excited atrial fibrillation or flutter (WPW syndrome) 1, 2
  • Do not use in patients with AV block greater than first degree or significant SA node dysfunction 1
  • Use with caution in patients with heart failure or impaired ventricular function 1
  • Avoid in patients with hypotension (systolic BP <90 mmHg) 1
  • Use caution when administering with other drugs that decrease peripheral resistance, myocardial filling, contractility, or electrical impulse propagation 2

Management of Adverse Effects

  • For hypotension: Place patient in Trendelenburg position and administer IV fluids 2
  • For severe bradycardia: Consider atropine or temporary pacing if needed 3
  • For worsening heart failure: Discontinue diltiazem and provide appropriate supportive care 1

Clinical Pearls

  • Heart rate reduction may last from 1-3 hours after bolus administration 2
  • Hypotension, if it occurs, is generally short-lived but may last from 1-3 hours 2
  • Diltiazem rarely converts atrial fibrillation/flutter to normal sinus rhythm but is highly effective for rate control 2
  • For PSVT, diltiazem has shown 88% effectiveness in converting to normal sinus rhythm 2

References

Guideline

Diltiazem Dosing for Paroxysmal Supraventricular Tachycardia (PSVT)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diltiazem Dosing for Coronary Vasospasm

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Low-dose diltiazem in atrial fibrillation with rapid ventricular response.

The American journal of emergency medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.